The Quantellect read.As of Nov 19, 2026, 10 active firms cover Taysha Gene Therapies Inc: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $10.00 to $17.00, a moderate spread. The average target of $12.78 sits 220% above the current $4.00. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.78
+219.8% upside
Average target across 9 active firms as of Nov 19, 2026 vs $4.00 current
Highest Target$17.00
Average Target$12.78
Lowest Target$10.00
Detailed analyst forecasts for TSHA
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate TSHA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TSHA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.13 – $-0.08 · 4 analysts · -6% YoY
Next period, 4 analysts expect Taysha Gene Therapies Inc to earn $-0.10 a share (range $-0.13 – $-0.08), versus $-0.11 a year earlier. Full-year consensus is $-0.43, growing to $-0.39 the year after.
REVENUE · NEXT QUARTER
$600.0K
Range $0 – $3.8M · 4 analysts
Revenue is expected to reach $600.0K (range $0 – $3.8M). Full-year consensus is $300.0K, rising to $19.5M next year.
Top analysts covering Taysha Gene Therapies Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TSHA.
#1
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$11.00+175.3% to target
Overall win rate
51%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #104
Buy
$12.00+200.4% to target
Overall win rate
43%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$19.00+375.6% to target
Overall win rate
38%
+ Follow
#4
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$17.00+325.5% to target
Overall win rate
35%
+ Follow
#5
Gil Blum
Needham · Rank #409
Buy
$12.00+200.4% to target
Overall win rate
27%
+ Follow
TSHA stock forecast FAQ
What is TSHA's average 12-month price target?+
The 9 active firms with a live target average $12.78 for Taysha Gene Therapies Inc over the next 12 months, ranging from a $17.00 high to a $10.00 low, as of Nov 19, 2026.
Is TSHA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TSHA?+
The Street-high target is $17.00 (Canaccord Genuity), and the Street-low is $10.00 (B of A Securities). The average of all 9 active-firm targets is $12.78.
How many active Wall Street firms cover TSHA?+
10 active firms have a recognized rating on Taysha Gene Therapies Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TSHA?+
Among analysts who currently cover TSHA, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $11.00 target.
What is Taysha Gene Therapies Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.13 – $-0.08) across 4 analysts. Full-year EPS is projected at $-0.43, rising to $-0.39 the following year.
How much revenue is Taysha Gene Therapies Inc expected to report next quarter?+
Consensus revenue is $600.0K (range $0 – $3.8M). Full-year revenue is projected at $300.0K, growing to $19.5M next year.
Have analysts been upgrading or downgrading TSHA lately?+
As of Nov 19, 2026, 10 of 10 active firms rate TSHA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TSHA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.